5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Starting soon · Not applicable
Conditions studied: Lung Cancer, Breast Cancer
In brief
This study aims to evaluate a novel 5T4 targeted nanobody PET imaging tracer, 68Ga-MY, for the detection and evaluation of solid tumors. The 5T4 oncofoetal antigen is considered a valuable tumor-associated antigen, which is expressed in many different cancers, but is rarely expressed in normal adult tissues. And cell surface expression of 5T4 is an important property for antibody-targeted therapies. It has been shown that 5T4 is expressed on tumour-initiating cells (TICs) and associated with worse clinical outcome. Moreover, decreased adherence due to 5T4 expression may be associated with cancer spread. In this single-center, open-label, self-controlled study, approximately 20 patients with suspected or confirmed solid tumors will undergo PET/CT imaging using 68Ga-MY. The imaging results will be compared with 18F-FDG. The study will assess tracer uptake in tumor lesions and compare diagnostic performance between imaging methods. The results may help determine whether 68Ga-MY PET/CT can improve tumor detection, staging, and clinical evaluation in patients with solid tumors.
Key facts
- Study ID
- NCT07589101
- Run by
- Peking University Cancer Hospital & Institute
- People needed
- 20
- Starts
- 2026-06-01
- Expected to finish
- 2027-12-30
- Last updated by the study team
- 2026-05-15
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with solid tumors;
- Presence of measurable lesions on imaging examinations;
- Expected survival ≥12 weeks.
You may not qualify if…
- Severe hepatic or renal dysfunction;
- Women who are planning pregnancy, pregnant, or breastfeeding;
- Unable to remain in supine position for 30 minutes;
- Refusal to participate in this clinical study;
- Diagnosis of claustrophobia or other psychiatric disorders;
- Other conditions deemed by the investigator as inappropriate for participation in the trial.
Where it is running
- Beijing Cancer Hospital — Beijing, Beijing Municipality, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.